Six PDXs, representing 20.8% of the tumours in this study, harboured druggable somatic mutations, including PIK3CA p.H1047R and KRAS p.A146V in WHIM9, PIK3CA p.H1047R in WHIM16 and WHIM24, PIK3CA p.E545K in WHIM18, PIK3CA p.E542K in WHIM20 and SF3B1 p.K700E in WHIM26 (Supplementary Data 16). The gene discussed is KRAS; the disease is neoplasm.